In pretreated NSCLC patients, PD-1/PD-L1 inhibitors led to significantly better overall responses, a longer OS, and reduced overall toxicity compared with chemotherapy [16]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.